Jump to
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, unique in many respects among cardiovascular conditions, including its extreme clinical heterogeneity. Through the years, HCM has acquired the unfortunate reputation as an unrelenting disease with a highly unfavorable and generally grim prognosis, and largely without effective treatment strategies or acceptable expectation for longevity and quality of life.1 Many patients with HCM, based on evaluation in general cardiology practices, have come to mistakenly believe that their diagnosis is among the least favorable that could confront them.
Recent Outcome Data
This highly negative perception, created in part by early reports of cohorts impacted by patient referral bias, persists despite recent major advances in diagnosis and treatment, including advanced imaging, contemporary risk stratification, and implantable cardioverter-defibrillators for sudden death prevention2; surgical septal myectomy, alcohol ablation, and heart transplant to reverse progressive heart failure; prophylactic anticoagulation to prevent embolic stroke; and defibrillation and targeted temperature management for out-of-hospital cardiac arrest.1 …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Jump to
Article Tools
Share this Article
- Perspectives on the Overall Risks of Living With Hypertrophic CardiomyopathyPermalink:
